_id
6919eccb3c536f8df2318418
Ticker
POLB.LSE
Name
Poolbeg Pharma PLC
Exchange
LSE
Address
40 Bank Street, London, United Kingdom, E14 5NR
Country
UK
Sector
Healthcare
Industry
Biotechnology
Currency
GBX
Website
https://www.poolbegpharma.com
Description
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
Last Close
40000
Volume
180928
Current Price
4.8751
Change
0
Last Updated
2025-12-30T11:23:30.689Z
Image
https://logo.clearbit.com/www.poolbegpharma.com
Ipo Date
-
Market Cap
27888000
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
-
Cost Of Revenue
26000
Gross Profit
-26000
Operating Expenses
2532000
Operating Income
-2558000
Interest Expense
-
Pretax Income
-2233000
Net Income
-2178000
Eps
-0.004299784471625299
Dividends Per Share
-
Shares Outstanding
697200000
Income Tax Expense
-55000
EBITDA
-2207000
Operating Margin
-
Total Other Income Expense Net
325000
Cash
9961000
Short Term Investments
-
Receivables
738000
Inventories
-
Total Current Assets
10699000
Property Plant Equipment
-
Total Assets
12361000
Payables
429000
Short Term Debt
-
Long Term Debt
-
Total Liabilities
429000
Equity
11932000
Bs_currency_symbol
GBP
Depreciation
26000
Change In Working Capital
-489000
Cash From Operations
-2346000
Capital Expenditures
0
Cash From Investing
-4000
Cash From Financing
4487000
Net Change In Cash
2137000
Cf_currency_symbol
-
PE
-
PB
206.95764428232482
ROE
-18.25343613811599
ROA
-17.619933662325053
FCF
-2346000
Fcf Percent
-
Piotroski FScore
0
Health Score
34
Deep Value Investing Score
4.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
3
Quality Investing Score
3
Value Investing Score
5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
-
Quarters > 0 > income Statement > cost Of Revenue
26000
Quarters > 0 > income Statement > gross Profit
-26000
Quarters > 0 > income Statement > operating Expenses
2532000
Quarters > 0 > income Statement > operating Income
-2558000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-2233000
Quarters > 0 > income Statement > net Income
-2178000
Quarters > 0 > income Statement > eps
-0.004299784471625299
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
506537017
Quarters > 0 > income Statement > income Tax Expense
-55000
Quarters > 0 > income Statement > EBITDA
-2207000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
325000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
9961000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
738000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
10699000
Quarters > 0 > balance Sheet > property Plant Equipment
-
Quarters > 0 > balance Sheet > total Assets
12361000
Quarters > 0 > balance Sheet > payables
429000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
429000
Quarters > 0 > balance Sheet > equity
11932000
Quarters > 0 > balance Sheet > currency_symbol
GBP
Quarters > 0 > cash Flow > net Income
-2178000
Quarters > 0 > cash Flow > depreciation
26000
Quarters > 0 > cash Flow > change In Working Capital
-489000
Quarters > 0 > cash Flow > cash From Operations
-2346000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-4000
Quarters > 0 > cash Flow > cash From Financing
4487000
Quarters > 0 > cash Flow > net Change In Cash
2137000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.004299784471625299
Quarters > 0 > ratios > PB
206.95764428232482
Quarters > 0 > ratios > ROE
-18.25343613811599
Quarters > 0 > ratios > ROA
-17.619933662325053
Quarters > 0 > ratios > FCF
-2346000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
34
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
101000
Quarters > 1 > income Statement > gross Profit
-101000
Quarters > 1 > income Statement > operating Expenses
3843000
Quarters > 1 > income Statement > operating Income
-3843000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-3661000
Quarters > 1 > income Statement > net Income
-3532000
Quarters > 1 > income Statement > eps
-0.007064
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
500000000
Quarters > 1 > income Statement > income Tax Expense
129000
Quarters > 1 > income Statement > EBITDA
-3481000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
182000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
7824000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
519000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
8563000
Quarters > 1 > balance Sheet > property Plant Equipment
-
Quarters > 1 > balance Sheet > total Assets
10247000
Quarters > 1 > balance Sheet > payables
165000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
974000
Quarters > 1 > balance Sheet > equity
9273000
Quarters > 1 > balance Sheet > currency_symbol
GBP
Quarters > 1 > cash Flow > net Income
-3532000
Quarters > 1 > cash Flow > depreciation
101000
Quarters > 1 > cash Flow > change In Working Capital
157000
Quarters > 1 > cash Flow > cash From Operations
-2384000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
147000
Quarters > 1 > cash Flow > cash From Financing
-
Quarters > 1 > cash Flow > net Change In Cash
-10061000
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.007064
Quarters > 1 > ratios > PB
262.8653078831015
Quarters > 1 > ratios > ROE
-38.089075811495746
Quarters > 1 > ratios > ROA
-34.46862496340392
Quarters > 1 > ratios > FCF
-2384000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
-
Quarters > 2 > income Statement > cost Of Revenue
13000
Quarters > 2 > income Statement > gross Profit
-13000
Quarters > 2 > income Statement > operating Expenses
2801000
Quarters > 2 > income Statement > operating Income
-2814000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-2283000
Quarters > 2 > income Statement > net Income
-2258000
Quarters > 2 > income Statement > eps
-4.516
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
500000
Quarters > 2 > income Statement > income Tax Expense
-25000
Quarters > 2 > income Statement > EBITDA
-2270000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
531000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
10061000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
11000
Quarters > 2 > balance Sheet > inventories
627000
Quarters > 2 > balance Sheet > total Current Assets
10999000
Quarters > 2 > balance Sheet > property Plant Equipment
-
Quarters > 2 > balance Sheet > total Assets
13010000
Quarters > 2 > balance Sheet > payables
561000
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
561000
Quarters > 2 > balance Sheet > equity
12449000
Quarters > 2 > balance Sheet > currency_symbol
GBP
Quarters > 2 > cash Flow > net Income
-2258
Quarters > 2 > cash Flow > depreciation
13
Quarters > 2 > cash Flow > change In Working Capital
-10
Quarters > 2 > cash Flow > cash From Operations
-2262
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
152
Quarters > 2 > cash Flow > cash From Financing
-
Quarters > 2 > cash Flow > net Change In Cash
-1055
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-4.516
Quarters > 2 > ratios > PB
0.1958028757329906
Quarters > 2 > ratios > ROE
-18.138003052454014
Quarters > 2 > ratios > ROA
-17.35588009223674
Quarters > 2 > ratios > FCF
-2262
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
42
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
-
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
1264.5
Quarters > 3 > income Statement > operating Income
-1264.5
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-1141.5
Quarters > 3 > income Statement > net Income
-1129000
Quarters > 3 > income Statement > eps
-2.258
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
500000
Quarters > 3 > income Statement > income Tax Expense
12.5
Quarters > 3 > income Statement > EBITDA
-1258
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
123
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
10061000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
11000
Quarters > 3 > balance Sheet > inventories
627000
Quarters > 3 > balance Sheet > total Current Assets
10999000
Quarters > 3 > balance Sheet > property Plant Equipment
-
Quarters > 3 > balance Sheet > total Assets
13010000
Quarters > 3 > balance Sheet > payables
561000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
561000
Quarters > 3 > balance Sheet > equity
12449000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-1129
Quarters > 3 > cash Flow > depreciation
6.5
Quarters > 3 > cash Flow > change In Working Capital
-5
Quarters > 3 > cash Flow > cash From Operations
-1131
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
-
Quarters > 3 > cash Flow > net Change In Cash
-1055
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-2.258
Quarters > 3 > ratios > PB
0.1958028757329906
Quarters > 3 > ratios > ROE
-9.069001526227007
Quarters > 3 > ratios > ROA
-8.67794004611837
Quarters > 3 > ratios > FCF
-1131
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
42
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
114000
Annuals > 0 > income Statement > gross Profit
-114000
Annuals > 0 > income Statement > operating Expenses
6372000
Annuals > 0 > income Statement > operating Income
-6618000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-5944000
Annuals > 0 > income Statement > net Income
-5790000
Annuals > 0 > income Statement > eps
-0.01158
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
500000000
Annuals > 0 > income Statement > income Tax Expense
154000
Annuals > 0 > income Statement > EBITDA
-5997000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
674000
Annuals > 0 > income Statement > currency_symbol
GBP
Annuals > 0 > balance Sheet > cash
7824000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
519000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
8563000
Annuals > 0 > balance Sheet > property Plant Equipment
-
Annuals > 0 > balance Sheet > total Assets
10247000
Annuals > 0 > balance Sheet > payables
165000
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
974000
Annuals > 0 > balance Sheet > equity
9273000
Annuals > 0 > balance Sheet > currency_symbol
GBP
Annuals > 0 > cash Flow > net Income
-5944000
Annuals > 0 > cash Flow > depreciation
114000
Annuals > 0 > cash Flow > change In Working Capital
135000
Annuals > 0 > cash Flow > cash From Operations
-4646000
Annuals > 0 > cash Flow > capital Expenditures
129000
Annuals > 0 > cash Flow > cash From Investing
299000
Annuals > 0 > cash Flow > cash From Financing
-
Annuals > 0 > cash Flow > net Change In Cash
-4347000
Annuals > 0 > cash Flow > currency_symbol
GBP
Annuals > 0 > ratios > PE
-0.01158
Annuals > 0 > ratios > PB
212.66041194866818
Annuals > 0 > ratios > ROE
-62.43934001941119
Annuals > 0 > ratios > ROA
-56.50434273445887
Annuals > 0 > ratios > FCF
-4775000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
26
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
26000
Annuals > 1 > income Statement > gross Profit
-26000
Annuals > 1 > income Statement > operating Expenses
5039000
Annuals > 1 > income Statement > operating Income
-5039000
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-4505000
Annuals > 1 > income Statement > net Income
-3931000
Annuals > 1 > income Statement > eps
-7.862
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
500000
Annuals > 1 > income Statement > income Tax Expense
-574000
Annuals > 1 > income Statement > EBITDA
-4660000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
534000
Annuals > 1 > income Statement > currency_symbol
GBP
Annuals > 1 > balance Sheet > cash
12171000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
700000
Annuals > 1 > balance Sheet > inventories
-1327000
Annuals > 1 > balance Sheet > total Current Assets
13498000
Annuals > 1 > balance Sheet > property Plant Equipment
-
Annuals > 1 > balance Sheet > total Assets
15428000
Annuals > 1 > balance Sheet > payables
79000
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
986000
Annuals > 1 > balance Sheet > equity
14442000
Annuals > 1 > balance Sheet > currency_symbol
GBP
Annuals > 1 > cash Flow > net Income
-3931000
Annuals > 1 > cash Flow > depreciation
26000
Annuals > 1 > cash Flow > change In Working Capital
209
Annuals > 1 > cash Flow > cash From Operations
-4381000
Annuals > 1 > cash Flow > capital Expenditures
175000
Annuals > 1 > cash Flow > cash From Investing
359000
Annuals > 1 > cash Flow > cash From Financing
-
Annuals > 1 > cash Flow > net Change In Cash
-4022000
Annuals > 1 > cash Flow > currency_symbol
GBP
Annuals > 1 > ratios > PE
-7.862
Annuals > 1 > ratios > PB
0.13654618473895583
Annuals > 1 > ratios > ROE
-27.219221714443982
Annuals > 1 > ratios > ROA
-25.479647394347936
Annuals > 1 > ratios > FCF
-4556000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
34
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
26000
Annuals > 2 > income Statement > gross Profit
-26000
Annuals > 2 > income Statement > operating Expenses
4986000
Annuals > 2 > income Statement > operating Income
-4986000
Annuals > 2 > income Statement > interest Expense
-
Annuals > 2 > income Statement > pretax Income
-4777000
Annuals > 2 > income Statement > net Income
-4686000
Annuals > 2 > income Statement > eps
-9.372
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
500000
Annuals > 2 > income Statement > income Tax Expense
-91000
Annuals > 2 > income Statement > EBITDA
-4751000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
209000
Annuals > 2 > income Statement > currency_symbol
GBP
Annuals > 2 > balance Sheet > cash
16193000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
962000
Annuals > 2 > balance Sheet > inventories
-962
Annuals > 2 > balance Sheet > total Current Assets
17155000
Annuals > 2 > balance Sheet > property Plant Equipment
-
Annuals > 2 > balance Sheet > total Assets
19289000
Annuals > 2 > balance Sheet > payables
293000
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
966000
Annuals > 2 > balance Sheet > equity
18323000
Annuals > 2 > balance Sheet > currency_symbol
GBP
Annuals > 2 > cash Flow > net Income
-4777000
Annuals > 2 > cash Flow > depreciation
26000
Annuals > 2 > cash Flow > change In Working Capital
72000
Annuals > 2 > cash Flow > cash From Operations
-4368000
Annuals > 2 > cash Flow > capital Expenditures
597000
Annuals > 2 > cash Flow > cash From Investing
-388000
Annuals > 2 > cash Flow > cash From Financing
-
Annuals > 2 > cash Flow > net Change In Cash
-4756000
Annuals > 2 > cash Flow > currency_symbol
GBP
Annuals > 2 > ratios > PE
-9.372
Annuals > 2 > ratios > PB
0.10762429733122304
Annuals > 2 > ratios > ROE
-25.574414670086774
Annuals > 2 > ratios > ROA
-24.293638861527295
Annuals > 2 > ratios > FCF
-4965000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
33
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
18000
Annuals > 3 > income Statement > gross Profit
-18000
Annuals > 3 > income Statement > operating Expenses
2360000
Annuals > 3 > income Statement > operating Income
-2378000
Annuals > 3 > income Statement > interest Expense
0
Annuals > 3 > income Statement > pretax Income
-2336000
Annuals > 3 > income Statement > net Income
-2336000
Annuals > 3 > income Statement > eps
-4.672
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
500000
Annuals > 3 > income Statement > income Tax Expense
42000
Annuals > 3 > income Statement > EBITDA
-2318000
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
42000
Annuals > 3 > income Statement > currency_symbol
GBP
Annuals > 3 > balance Sheet > cash
20949000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
8000
Annuals > 3 > balance Sheet > inventories
0
Annuals > 3 > balance Sheet > total Current Assets
21455000
Annuals > 3 > balance Sheet > property Plant Equipment
-
Annuals > 3 > balance Sheet > total Assets
23018000
Annuals > 3 > balance Sheet > payables
79000
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
438000
Annuals > 3 > balance Sheet > equity
22580000
Annuals > 3 > balance Sheet > currency_symbol
GBP
Annuals > 3 > cash Flow > net Income
-2336000
Annuals > 3 > cash Flow > depreciation
18000
Annuals > 3 > cash Flow > change In Working Capital
-68000
Annuals > 3 > cash Flow > cash From Operations
-2146000
Annuals > 3 > cash Flow > capital Expenditures
81000
Annuals > 3 > cash Flow > cash From Investing
-81000
Annuals > 3 > cash Flow > cash From Financing
23176000
Annuals > 3 > cash Flow > net Change In Cash
20949000
Annuals > 3 > cash Flow > currency_symbol
GBP
Annuals > 3 > ratios > PE
-4.672
Annuals > 3 > ratios > PB
0.08733392382639504
Annuals > 3 > ratios > ROE
-10.345438441098317
Annuals > 3 > ratios > ROA
-10.148579372664871
Annuals > 3 > ratios > FCF
-2227000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
33
Valuation > metrics > PE
-0.004299784471625299
Valuation > metrics > PB
206.95764428232482
Valuation > final Score
20
Valuation > verdict
6798.6% Overvalued
Profitability > metrics > ROE
-18.25343613811599
Profitability > metrics > ROA
-20.35704271427236
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.03595373784780422
Risk > metrics > Interest Coverage
-98.38461538461539
Risk > final Score
-334
Risk > verdict
High
Liquidity > metrics > Current Ratio
24.939393939393938
Liquidity > metrics > Quick Ratio
24.939393939393938
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
-25
Prev Risks > 1
-806
Prev Risks > 2
17
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T23:03:19.118Z
Earnings History > 0 > period
2026-03-31
Earnings History > 0 > report Date
2026-05-18
Earnings History > 0 > date
2026-03-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-09-29
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.0043
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
-0.0043
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-27
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.01
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
-0.01
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2023-03-31
Earnings History > 3 > report Date
2023-04-12
Earnings History > 3 > date
2023-03-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
GBP
Earnings History > 3 > eps Actual
-0.01
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
-0.01
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2022-06-30
Earnings History > 4 > report Date
2022-09-06
Earnings History > 4 > date
2022-06-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
GBP
Earnings History > 4 > eps Actual
0
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
-
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
Stock Price
GBp 0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/APoolbeg Pharma within FTSE AIM Focus on Clinical Progress and Research Direction - Kalkine Media
12/18/2025
Poolbeg Pharma within FTSE AIM Focus on Clinical Progress and Research Direction Kalkine Media
Read more →RNS Hotlist with Zak Mir: WCAP, HVO, POLB, ZPHR, GRX, ASTR, ZEN, GEX & CMCX Share Talk
Read more →Showing 2 of 6
(Last Updated 2025-06-30)
Rating:
BUY
$
Analyst Picks
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Poolbeg Pharma PLC
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2026-03-31
EPS Estimate
—
Date
2025-06-30
EPS Actual
-0.0043
EPS Estimate
0
EPS Difference
-0.0043
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
£ 0
Cost Of Revenue
£ 0
Gross Profit
£ 0
Operating Expenses
£ 0
Operating Income
£ 0
Interest Expense
£ 0
Pretax Income
£ 0
Net Income
£ 0
Income Tax Expense
£ 0
EBITDA
£ 0
Total Other Income Expense Net
£ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
£ 0
Short Term Investments
£ 0
Receivables
£ 0
Inventories
£ 0
Total Current Assets
£ 0
Property Plant Equipment
£ 0
Total Assets
£ 0
Payables
£ 0
Short Term Debt
£ 0
Long Term Debt
£ 0
Total Liabilities
£ 0
Equity
£ 0
(Last Updated 2025-06-30)
Net Income
£ 0
Depreciation
£ 0
Change In Working Capital
£ 0
Cash From Operations
£ 0
Capital Expenditures
£ 0
Cash From Investing
£ 0
Cash From Financing
£ 0
Net Change In Cash
£ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.